Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYCLONE 3: abemaciclib added to abiraterone plus prednisone for high-risk metastatic hormone-sensitive prostate cancer
NL-OMON59412Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Abemaciclib + abiraterone + prednisone with Placebo + abiraterone + prednisone (2 arms). Primary endpoint: Radiographic progression-free survival. Started Oct 2022; status: completed.
02
Drugs
abemaciclibabirateroneprednisone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON59412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59412.